ticlopidine and Benign Neoplasms studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Research Excerpts

Excerpt	Relevance	Reference
"The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial enrolled 9326 participants with ACS, who received aspirin plus clopidogrel or prasugrel."	9.22	Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. ( Armstrong, PW; Beaven, AW; Blackwell, KL; Cyr, DD; Eckart, D; Fox, KA; Houterloot, L; Morse, MA; Ohman, EM; Onken, JE; Prabhakaran, D; Ready, NE; Roe, MT; Schulte, PJ; Strickler, JH; White, HD; Winters, KJ; Wiviott, SD; Zafar, SY; Zamoryakhin, D, 2016)
"The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial enrolled 9326 participants with ACS, who received aspirin plus clopidogrel or prasugrel."	5.22	Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. ( Armstrong, PW; Beaven, AW; Blackwell, KL; Cyr, DD; Eckart, D; Fox, KA; Houterloot, L; Morse, MA; Ohman, EM; Onken, JE; Prabhakaran, D; Ready, NE; Roe, MT; Schulte, PJ; Strickler, JH; White, HD; Winters, KJ; Wiviott, SD; Zafar, SY; Zamoryakhin, D, 2016)
"(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months."	3.75	Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009)
"Thrombotic thrombocytopenic purpura is a thrombotic microangiopathy related to a severe deficiency of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13; activity <10%)."	2.82	Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. ( Azoulay, E; Benhamou, Y; Boisseau, P; Coppo, P; de Maistre, E; Delmas, Y; Galicier, L; Mariotte, E; Perez, P; Poullin, P; Provôt, F; Rondeau, E; Stepanian, A; Veyradier, A; Zouiti, F, 2016)
"Subanalyses according to cancer location showed that thienopyridines are not significantly associated with malignancy mortality and/or incidence."	2.55	Cancer Event Rate and Mortality with Thienopyridines: A Systematic Review and Meta-Analysis. ( Kinnaird, T; Kotronias, RA; Kwok, CS; Mamas, MA; Wong, CW; Zaman, A, 2017)
"In lay terms "cancers follow bleeding", which seems to be true for antithrombotic agents in general."	2.52	Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. ( Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Serebruany, VL, 2015)
"Proton pump (H(+)/K(+)-adenosine triphosphatase) inhibitors (PPIs) are widely used to treat patients with acid-related disorders because they are generally perceived to be safe and effective."	2.46	Safety of proton pump inhibitor exposure. ( Metz, DC; Yang, YX, 2010)
"Hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), and several other conditions are associated with TMA."	2.44	The thrombotic microangiopathies. ( Copelovitch, L; Kaplan, BS, 2008)
"The optimal duration and cancer risks of antiplatelet therapy following percutaneous coronary intervention (PCI) are unclear."	1.46	Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA). ( Cabrera-Fuentes, HA; Cho, YR; Kim, MH; Kim, YD; Lee, K; Park, K; Park, TH; Serebruany, VL; Yoon, SC, 2017)
"ESSENTIALS: Cancer patients have a high rate of venous thrombosis (VT) but the underlying mechanisms are unknown."	1.43	Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. ( Bergmeier, W; Boulaftali, Y; Cooley, BC; Dee, R; Fuentes, R; Geddings, JE; Getz, TM; Hisada, Y; Key, NS; Mackman, N; Whelihan, M; Wolberg, AS, 2016)
"Approaches to the treatment of acute coronary syndrome in patients with thrombocytopenia might be better directed toward the evaluation of platelet function rather than toward absolute platelet count, and the risk-benefit equation of invasive procedures and antithrombotic therapies may need to incorporate this information."	1.36	Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. ( Bathina, JD; Daher, IN; Durand, JB; Iliescu, C; Yusuf, SW, 2010)

Research

Studies (22)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Percentage of Participants With a Composite Endpoint of All-cause Death, MI, or Stroke

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (9.09)	29.6817
2010's	19 (86.36)	24.3611
2020's	1 (4.55)	2.80

Authors	Studies
Tesei, A	1
Cortesi, M	1
Bedeschi, M	1
Marino, N	1
Rossino, G	1
Listro, R	1
Rossi, D	1
Linciano, P	1
Collina, S	1
Levine, M	1
Serebruany, VL	4
Geddings, JE	1
Hisada, Y	1
Boulaftali, Y	1
Getz, TM	1
Whelihan, M	1
Fuentes, R	1
Dee, R	1
Cooley, BC	1
Key, NS	1
Wolberg, AS	1
Bergmeier, W	1
Mackman, N	1
Cherepanov, V	1
Cabrera-Fuentes, HA	2
Kim, MH	2
Roe, MT	1
Cyr, DD	1
Eckart, D	1
Schulte, PJ	1
Morse, MA	1
Blackwell, KL	1
Ready, NE	1
Zafar, SY	1
Beaven, AW	1
Strickler, JH	1
Onken, JE	1
Winters, KJ	1
Houterloot, L	1
Zamoryakhin, D	1
Wiviott, SD	1
White, HD	1
Prabhakaran, D	1
Fox, KA	1
Armstrong, PW	1
Ohman, EM	1
Otoshi, T	1
Kataoka, Y	1
Nakagawa, A	1
Otsuka, K	1
Tomii, K	1
Mariotte, E	1
Azoulay, E	1
Galicier, L	1
Rondeau, E	1
Zouiti, F	1
Boisseau, P	1
Poullin, P	1
de Maistre, E	1
Provôt, F	1
Delmas, Y	1
Perez, P	1
Benhamou, Y	1
Stepanian, A	1
Coppo, P	1
Veyradier, A	1
Kotronias, RA	1
Kwok, CS	1
Wong, CW	1
Kinnaird, T	1
Zaman, A	1
Mamas, MA	1
Leader, A	1
Zelikson-Saporta, R	1
Pereg, D	1
Spectre, G	1
Rozovski, U	1
Raanani, P	1
Hermoni, D	1
Lishner, M	1
Lee, K	1
Cho, YR	1
Park, K	1
Park, TH	1
Kim, YD	1
Yoon, SC	1
Yusuf, SW	1
Iliescu, C	1
Bathina, JD	1
Daher, IN	1
Durand, JB	1
Yang, YX	1
Metz, DC	1
Cattaneo, M	1
Wang, L	1
McLeod, HL	1
Weinshilboum, RM	1
Lee, DK	1
Choi, Y	1
Shon, SM	1
Schellingerhout, D	1
Park, JE	1
Kim, DE	1
Labos, C	1
Dasgupta, K	1
Nedjar, H	1
Turecki, G	1
Rahme, E	1
Salari, K	1
Watkins, H	1
Ashley, EA	1
Ravid, M	1
Copelovitch, L	1
Kaplan, BS	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998]	Phase 3	9,326 participants (Actual)	Interventional	2008-06-30	Completed
ADAMTS13-related Prognostic Factors in Adult and Pediatric Thrombotic Thrombocytopenic Purpura[NCT00426686]		153 participants (Actual)	Observational	2006-11-30	Completed
DART Registry: Diagnosing Adverse Drug Reactions Registry[NCT01970709]		250,000 participants (Anticipated)	Observational [Patient Registry]	2013-11-30	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke

Intervention	percentage of participants with an event (Number)
Prasugrel: <75 Years of Age	10.61
Prasugrel: 75 Years of Age or Older	27.04
Clopidogrel: <75 Years of Age	11.12
Clopidogrel: 75 Years of Age or Older	26.83

The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Percentage of Participants With a Composite Endpoint of CV Death and MI

Intervention	percentage of participants with an event (Number)
Prasugrel: <75 Years of Age	10.06
Prasugrel: 75 Years of Age or Older	24.64
Clopidogrel: <75 Years of Age	10.96
Clopidogrel: 75 Years of Age or Older	24.13

The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Percentage of Participants With a Composite Endpoint of CV Death, MI, Stroke, or Re-hospitalization for Recurrent Unstable Angina (UA)

Intervention	percentage of participants with an event (Number)
Prasugrel: <75 Years of Age	9.61
Prasugrel: 75 Years of Age or Older	22.53
Clopidogrel: <75 Years of Age	10.21
Clopidogrel: 75 Years of Age or Older	22.69

The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Biomarker Measurements of Inflammation/Hemodynamic Stress: Brain Natriuretic Peptide (BNP)

Intervention	percentage of participants with an event (Number)
Prasugrel: <75 Years of Age	12.13
Prasugrel: 75 Years of Age or Older	26.27
Clopidogrel: <75 Years of Age	12.83
Clopidogrel: 75 Years of Age or Older	25.67

Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months

Biomarker Measurements of Inflammation/Hemodynamic Stress: C-Reactive Protein (CRP)

Intervention	picograms per milliliter (pg/mL) (Geometric Mean)
	Day 30	6 Months (n=725, 125, 701, 174)
Clopidogrel: <75 Years of Age	319.345	250.982
Clopidogrel: 75 Years of Age or Older	951.359	722.750
Prasugrel: <75 Years of Age	313.494	253.434
Prasugrel: 75 Years of Age or Older	1082.396	770.132

C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6

Economic and Quality of Life Outcomes

Intervention	milligrams per liter (mg/L) (Geometric Mean)
	Day 30	6 Months (n=755, 143, 745, 178)
Clopidogrel: <75 Years of Age	2.287	2.149
Clopidogrel: 75 Years of Age or Older	2.226	1.543
Prasugrel: <75 Years of Age	2.330	2.272
Prasugrel: 75 Years of Age or Older	2.441	1.593

Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)

Genotyping Related to Drug Metabolism

Intervention	units on a scale (Mean)
	Baseline, physical limitations	Baseline, angina frequency	24 Months, physical limitations (n=420, 412)	24 Months, angina frequency (n=420, 412)
Clopidogrel	67.0	73.1	74.5	89.5
Prasugrel	67.8	73.6	75.1	89.7

Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline

Platelet Aggregation Measures

Intervention	percentage participants with geneotype (Number)
	UM, 1/17	UM, 17/17	EM (non-UM), 1/1	IM, 1/2	IM, 1/3	IM, 1/4	IM, 1/6	IM, 1/8	PM, 2/2	PM, 2/3	PM, 2/4	PM, 2/6	PM, 2/8	PM, 3/3	UNK, 1/10	UNK, 1/13	UNK, 1/9	UNK, 1/9, 9/17	UNK, 13/17	UNK, 2/13	UNK, 2/17	UNK, 2/9	UNK, 3/17	UNK, 4/17	UNK, 4/9	UNK, 6/17	UNK, 8/17	UNK, 9/17	UNK, Undefined genotype
Clopidogrel: <75 Years of Age	25.1	5.4	35.7	19.8	0.5	0.1	0.0	0.4	4.3	0.3	0.2	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	6.8	0.1	0.0	0.2	0.0	0.0	0.1	0.0	0.5
Clopidogrel: 75 Years of Age or Older	21.8	4.3	41.2	19.7	0.6	0.3	0.2	0.3	3.8	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.2	0.0	0.3	0.0	0.0	0.2	0.0	0.0	0.6
Prasugrel: <75 Years of Age	24.0	5.1	38.8	18.6	0.8	0.4	0.0	0.1	3.9	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	6.3	0.0	0.1	0.2	0.0	0.0	0.2	0.0	0.7
Prasugrel: 75 Years of Age or Older	25.0	3.6	42.1	18.3	0.6	0.0	0.2	0.5	2.2	0.2	0.2	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	6.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.6

Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months

Summary of All Deaths

Intervention	P2Y12 Reaction Units (PRU) (Least Squares Mean)
	Day 30	Month 12 (n=386, 76, 400, 103)
Clopidogrel: <75 Years of Age	193.489	199.003
Clopidogrel: 75 Years of Age or Older	200.285	181.360
Prasugrel: <75 Years of Age	93.280	94.529
Prasugrel: 75 Years of Age or Older	151.872	135.096

All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)

Article	Year
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. Thrombosis and haemostasis, 2015, Nov-25, Volume: 114, Issue:6 Topics: Adenosine; Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Carcinogenicity Tests; Clopid	2015
Cancer Event Rate and Mortality with Thienopyridines: A Systematic Review and Meta-Analysis. Drug safety, 2017, Volume: 40, Issue:3 Topics: Aspirin; Clopidogrel; Humans; Incidence; Neoplasms; Platelet Aggregation Inhibitors; Prasugrel Hydro	2017
Safety of proton pump inhibitor exposure. Gastroenterology, 2010, Volume: 139, Issue:4 Topics: Animals; Bone and Bones; Calcium; Clopidogrel; Drug Interactions; Humans; Iron; Magnesium; Neoplasms	2010
Genomics and drug response. The New England journal of medicine, 2011, Mar-24, Volume: 364, Issue:12 Topics: Anti-Infective Agents; Antineoplastic Agents; Aromatase Inhibitors; Cardiovascular Agents; Clopidogr	2011
Personalized medicine: hope or hype? European heart journal, 2012, Volume: 33, Issue:13 Topics: Anticoagulants; Cardiovascular Diseases; Clopidogrel; Genetic Predisposition to Disease; Genetic Tes	2012
The thrombotic microangiopathies. Pediatric nephrology (Berlin, Germany), 2008, Volume: 23, Issue:10 Topics: Hematopoietic Stem Cell Transplantation; Hemolytic-Uremic Syndrome; HIV Infections; Humans; Lupus Er	2008

Article	Year
Repurposing the Antiplatelet Agent Ticlopidine to Counteract the Acute Phase of ER Stress Condition: An Opportunity for Fighting Coronavirus Infections and Cancer. Molecules (Basel, Switzerland), 2022, Jul-06, Volume: 27, Issue:14 Topics: COVID-19 Drug Treatment; Drug Repositioning; Endoplasmic Reticulum Stress; Humans; Neoplasms; Platel	2022
Aspirin plus clopidogrel was not linked to risk for cancer compared with aspirin alone or no antiplatelets. Annals of internal medicine, 2017, 07-18, Volume: 167, Issue:2 Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Neoplasms; Platelet Aggregation Inhibitors;	2017
Redesigning TRACER trial after TRITON. International journal of cardiology, 2015, Oct-15, Volume: 197 Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Drug Thera	2015
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events. International journal of cardiology, 2015, Dec-15, Volume: 201 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mor	2015
Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:1 Topics: Adenocarcinoma; Animals; Blood Platelets; Cell Line, Tumor; Cell-Derived Microparticles; Clopidogrel	2016
Clinical Features and Outcomes of Diffuse Alveolar Hemorrhage During Antithrombotic Therapy: A Retrospective Cohort Study. Lung, 2016, Volume: 194, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Connective Tissue Diseases; Female	2016
The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence. The American journal of medicine, 2017, Volume: 130, Issue:7 Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Incidence;	2017
Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA). Thrombosis and haemostasis, 2017, 05-03, Volume: 117, Issue:5 Topics: Aged; Aspirin; Cause of Death; Chi-Square Distribution; Clopidogrel; Disease-Free Survival; Drug Adm	2017
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire international, 2009, Volume: 18, Issue:103 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr	2009
Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. Texas Heart Institute journal, 2010, Volume: 37, Issue:3 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogr	2010
Prasugrel and cancer. Archives of internal medicine, 2010, Nov-22, Volume: 170, Issue:21 Topics: Clinical Trials as Topic; Clopidogrel; Humans; Neoplasms; Piperazines; Platelet Aggregation Inhibito	2010
Atorvastatin and clopidogrel interfere with photosensitization in vitro. Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2011, Volume: 10, Issue:10 Topics: Animals; Anticholesteremic Agents; Aspirin; Atorvastatin; Cathepsin B; Cell Line; Clopidogrel; Hepta	2011
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2011, Nov-08, Volume: 183, Issue:16 Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag	2011
Carcinophobia in clinical research. Polskie Archiwum Medycyny Wewnetrznej, 2012, Volume: 122 Suppl 1 Topics: Angiotensin Receptor Antagonists; Animals; Biomedical Research; Causality; Clopidogrel; Cyclooxygena	2012

ticlopidine and Benign Neoplasms